[Pulmonary cytotoxicity induced by bleomycin and methotrexate]

Area of Science:

• Pulmonary Medicine
• Radiology
• Oncology

Background:

• Drug-induced pulmonary parenchymal injuries present with nonspecific clinical and radiographic findings, complicating early diagnosis.
• Chemotherapy agents are common culprits, affecting approximately 10% of patients and leading to lung tissue damage.
• Established diagnostic methods rely on drug history, clinical presentation, imaging, and excluding other causes.

Purpose of the Study:

• To highlight the diagnostic challenges of drug-induced pulmonary injuries.
• To emphasize the role of computed tomography (CT) in identifying and monitoring these conditions.
• To present clinical cases of pulmonary disease induced by specific chemotherapeutic agents.

Main Methods:

• Literature review of drug-induced pulmonary parenchymal disease.
• Analysis of diagnostic criteria, including clinical, radiological, and historical data.
• Case report presentation of bleomycin- and methotrexate-induced lung injury.

Main Results:

• Computed tomography (CT) demonstrates superior sensitivity for detecting, characterizing, and tracking drug-induced pulmonary disease compared to other methods.
• Specific chemotherapeutic agents like bleomycin and methotrexate can cause significant pulmonary parenchymal changes.
• Early identification of these injuries remains difficult due to overlapping symptoms with other lung conditions.

Conclusions:

• Computed tomography (CT) is the most effective imaging modality for diagnosing drug-induced pulmonary parenchymal disease.
• Awareness of potential drug-induced lung toxicities is crucial for clinicians managing patients on chemotherapy.
• Further research and standardized diagnostic protocols are needed to improve early detection and management.